OrlandoHealth

Summary

OrlandoHealth is a medical facility located in Orlando, Florida. This center is recognized for care of Breast Cancer, Pancreatic Cancer, Cancer, Melanoma, Lung Cancer and other specialties. OrlandoHealth is involved with conducting 190 clinical trials across 353 conditions. There are 32 research doctors associated with this hospital, such as Amy Smith, MD, Sajeve S. Thomas, Udayakumar Navaneethan, and Omar R. Kayaleh.

Top PIs

Clinical Trials running at OrlandoHealth

Endometrial Cancer

Pancreatic Cyst

Pancreatic Cancer

Breast Cancer

Emphysema

Obesity

Ovarian Cancer

Brain Tumor

Diabetes

Stroke

Lifileucel

for Endometrial Cancer

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

Recruiting

1 award

Phase 2

5 criteria

Methylated DNA Markers

for Endometrial Cancer Detection

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.

Recruiting

1 award

N/A

2 criteria

PARG Inhibitor

for Advanced Cancers

This trial is testing a new drug called IDE161 to see if it is safe and effective for patients with advanced cancers that have specific genetic changes. The drug works by preventing cancer cells from repairing their DNA, which can lead to their death.

Recruiting

1 award

Phase 1

4 criteria